Pharma giant Eli Lilly has inked a series of deals with four diabetes management companies to integrate with its forthcoming Tempo Pen and Tempo Smart Button products.
The companies that signed strategic international agreements with Eli Lilly are Dexcom, Glooko, myDiabby Healthcare and Roche.
Through the agreements, Eli Lilly’s Tempo Pen and connected Tempo Smart Button will integrate with the...
Despite coming out on top of analysts’ revenue predictions, Dexcom’s stock is tumbling after the company shared its first quarter of 2021 financial results.
As of Friday afternoon, Dexcom’s stock has fallen 6.3% from about $422 to $395.
Still, the company posted year-over-year growth for Q1 and increased its expectations for the remainder of the year.
“Dexcom is off to a great start in 2021,...
Dr. Amy Abernethy, Principal Deputy Commissioner and Acting Chief Information Officer at the FDA, will be stepping down from her positions at the agency in mid-to-late April, according to a memo Acting FDA Commissioner Dr. Janet Woodcock sent out to agency staff this morning.
Abernethy came to the agency in early 2019 following a long line of executive and board positions at healthcare and health...
Dexcom, a medtech device company best known for its continuous glucose monitoring systems, is launching a new venture fund aimed at investing in adjacent businesses.
Called Dexcom Ventures, the new investor will be zeroing in on sensing technology, data analytics, remote patient monitoring and population health. In fact, the new venture is expected to fund companies working in glucose sensing...
Despite the challenges of 2020, Dexcom was able to close the year out with financial growth for both the fourth quarter and the full year, according to its earnings report released Thursday.
In the earnings call, Dexcom’s chairman, president and CEO Kevin Sayer voiced his gratitude to the company for surpassing its goals even under the extreme circumstances last year.
“In any given year, these...
Teladoc Health has launched new pilots of its virtual primary care program and hopes to explore its take on a hospital-at-home offering with large health system partners before the end of the year, CEO Jason Gorevic said this week during a J.P. Morgan virtual presentation.
Shortly after the talk, Teladoc also announced a new pilot with continuous glucose monitor (CGM) company Dexcom for eligible...
Shortly before news broke that Teladoc was set to acquire Livongo, the chronic disease management company announced its quarterly earnings results. On Aug. 5 it announced that its second quarter total revenue came in at $91.9 million, which was up 125% YoY. The company reported a GAAP gross margin of 76.6% and non-GAAP gross margin of 77.3%.
The company attributed the gains to its growing...
Dexcom President and CEO Kevin Sayer is “incredibly proud” of what the company is calling “resilient growth” in the second quarter of 2020, according to an earnings call on Tuesday.
Despite having some uncertainty in the impacts of the COVID-19 pandemic, Dexcom was able to produce significant year-over-year growth in Q2 2020.
Sayer attributes much of the growth to a steady increase in knowledge...
Anthem has released its COVID-19-tracking and predictive digital platform, C19 Explorer, in partnership with CloudMedx. The tool has five data categories: public health, hospital, economy, social and preventative.
Users can view information on a national, state, county and city level with data on cases, deaths, unemployment, food insecurity and testing. C19 Explorer also includes future hot spot...
For years, Dexcom has been one of the leading competitors in the continuous glucose monitoring space. While the company is focused on looking ahead, that’s not to say there haven’t been some bumps in the road along the way.
In 2018, its Dexcom G6, an integrated continuous glucose monitoring system, got the green light from the FDA, making it the first interoperable CGM to get the designation....
.jpg?itok=BD5G-Yu_ "Shaking Hands")
_8_0.jpeg?itok=7-3NDPpQ)
.jpg?itok=n4N5nDjy)
